Crispr Theraptc (CRSP) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Crispr Theraptc (NASDAQ:CRSP) have received an average rating of “Buy” from the eight analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $23.00.
CRSP has been the subject of a number of research reports. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price target for the company. Cann initiated coverage on shares of Crispr Theraptc in a report on Monday, July 17th. They issued a “market perform” rating for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Chardan Capital reissued a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. Finally, Barclays PLC reissued a “buy” rating and issued a $29.00 price target on shares of Crispr Theraptc in a report on Friday, September 8th.
Crispr Theraptc (NASDAQ CRSP) opened at 18.95 on Tuesday. The firm has a 50-day moving average price of $19.03 and a 200-day moving average price of $19.03. Crispr Theraptc has a one year low of $13.75 and a one year high of $25.00. The firm’s market capitalization is $769.20 million.
Crispr Theraptc (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.06. The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 47.46%. The company’s quarterly revenue was up 350.0% on a year-over-year basis. Equities analysts anticipate that Crispr Theraptc will post ($2.43) earnings per share for the current year.
In other news, Director Kurt Von Emster sold 43,202 shares of Crispr Theraptc stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $16.90, for a total transaction of $730,113.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Rodger Novak sold 75,795 shares of Crispr Theraptc stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $20.25, for a total transaction of $1,534,848.75. Following the transaction, the chief executive officer now directly owns 1,232,697 shares in the company, valued at $24,962,114.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 673,071 shares of company stock worth $12,526,999. Insiders own 39.98% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. IHT Wealth Management LLC bought a new position in shares of Crispr Theraptc during the first quarter worth $110,000. Monashee Investment Management LLC lifted its position in Crispr Theraptc by 208.7% in the 1st quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after acquiring an additional 15,000 shares in the last quarter. Paulson & CO. Inc. bought a new stake in Crispr Theraptc in the 1st quarter valued at $1,099,000. Credit Suisse AG bought a new stake in Crispr Theraptc in the 1st quarter valued at $1,742,000. Finally, Wellington Management Group LLP lifted its position in Crispr Theraptc by 0.4% in the 1st quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after acquiring an additional 3,070 shares in the last quarter. 23.90% of the stock is currently owned by institutional investors.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.